<DOC>
	<DOCNO>NCT01452919</DOCNO>
	<brief_summary>The purpose study determine whether people schizophrenia take LY2140023 become physically dependent , experience series symptom crave drug stop use . This trial consist two phase : An open-label phase consist 4 week double-blind phase consist 3 week .</brief_summary>
	<brief_title>A Physical Dependence Study Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Clinical diagnosis schizophrenia Female patient childbearing potential must test negative pregnancy study entry agree use single , effective , medically acceptable method birth control Patients must require modification antipsychotic medication initiation antipsychotic medication , indicate present clinical psychiatric status and/or treatment tolerability outpatients Patients must consider reliable level understanding sufficient perform test examination require , willing perform study procedures Patients must able understand nature study give informed consent Have Clinical Global ImpressionSeverity Scale ( CGIS ) score &gt; 4 study entry Have psychiatric diagnosis addition schizophrenia Patients history inadequate clinical response antipsychotic treatment schizophrenia Patients receive adequate treatment trial , opinion investigator , clozapine dos &gt; 200 mg daily within 12 month prior study entry , receive clozapine month study entry Patients actively suicidal Female patient pregnant , nursing , intend become pregnant within 30 day complete study Have know , uncorrected , narrowangle glaucoma Patients electroconvulsive therapy ( ECT ) within 3 month study entry ECT time study Patients know medical history human immunodeficiency virus positive ( HIV+ ) status Patients test positive Hepatitis C virus antibody Hepatitis B surface antigen ( HBsAg ) without positive Hepatitis B core total antibody Patients current history seizure disorder , uncontrolled diabetes , certain disease liver , renal insufficiency , uncontrolled thyroid condition serious unstable illness Patients correct QT interval ( Bazett 's ; QTcB ) &gt; 450 millisecond ( msec ) ( male ) &gt; 470 msec ( female ) study entry ( base central vendor 's electrocardiogram [ ECG ] overread ) Have previously complete withdrawn study , study investigate LY2140023 predecessor molecule glutamatergic activity Are currently enrol , discontinue within last 60 day , clinical trial involve investigational product unapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>schizophrenia , LY2140023 , pomaglumetad methionil</keyword>
</DOC>